New Biomarkers Emerge for Predicting ADC Efficacy in Lung Cancer Treatment
The ICARUS-LUNG01 trial sheds light on why some lung cancer patients respond to antibody-drug conjugates while others resist.
Summary
A new commentary in Cancer Cell examines findings from ICARUS-LUNG01, a phase 2 clinical trial evaluating datopotamab deruxtecan — an antibody-drug conjugate — in patients with previously treated non-small cell lung cancer. The study, led by Planchard and colleagues, focused on identifying biomarkers that predict who will respond to this class of therapy and who will develop resistance. Antibody-drug conjugates work by delivering chemotherapy directly to cancer cells, but their effectiveness varies widely between patients. Understanding the biological factors that govern drug internalization, resistance mechanisms, and treatment response is critical for improving outcomes. This commentary highlights the growing effort to personalize lung cancer therapy by matching patients to treatments based on molecular profiles rather than tumor type alone.
Detailed Summary
Antibody-drug conjugates represent one of the most promising frontiers in oncology, combining the targeting precision of monoclonal antibodies with the cell-killing power of chemotherapy. Yet their clinical benefit is uneven — some patients respond dramatically while others progress quickly. Understanding why is now a central challenge in cancer medicine.
The ICARUS-LUNG01 trial, reported by Planchard et al. in Cancer Cell, is a phase 2 study evaluating datopotamab deruxtecan in patients with previously treated non-small cell lung cancer. Datopotamab deruxtecan targets TROP2, a protein frequently overexpressed in lung cancer cells, and delivers a cytotoxic payload directly to the tumor. The trial assessed both clinical activity and biomarkers associated with response and resistance.
This commentary by Sun, Zhao, Li, and Zhang from Sun Yat-Sen University Cancer Center contextualizes the trial's significance. The authors highlight that ICARUS-LUNG01 contributes meaningfully to the field's effort to characterize predictors of antibody-drug conjugate efficacy — particularly around drug internalization, a key step that determines how much cytotoxic payload actually reaches the cancer cell nucleus.
The implications are substantial for clinical practice. If reliable biomarkers can identify which patients are most likely to benefit from datopotamab deruxtecan, oncologists can make more informed treatment decisions, sparing non-responders from toxicity while prioritizing effective therapy for those who will respond. This aligns with the broader shift toward precision oncology in lung cancer management.
Caveats are important here. This commentary is based on a phase 2 trial, which is hypothesis-generating rather than practice-changing on its own. Larger confirmatory studies will be needed before biomarker-guided selection becomes standard. Additionally, this summary is based on the abstract only, limiting the depth of analysis available.
Key Findings
- ICARUS-LUNG01 evaluated datopotamab deruxtecan in previously treated non-small cell lung cancer patients.
- The trial identified biomarkers linked to antibody-drug conjugate efficacy and resistance mechanisms.
- Drug internalization is highlighted as a key determinant of therapeutic response to ADCs.
- Findings advance precision oncology efforts to match lung cancer patients to optimal ADC therapies.
- Resistance characterization may help spare non-responders from unnecessary toxicity.
Methodology
ICARUS-LUNG01 is a phase 2 clinical trial assessing the antibody-drug conjugate datopotamab deruxtecan in previously treated NSCLC patients. The study incorporated biomarker analyses alongside clinical efficacy endpoints. This article is a commentary contextualizing the trial's findings rather than a primary data report.
Study Limitations
This summary is based on the abstract only, as the full text is not open access, limiting the depth of methodological and results analysis. The commentary discusses a phase 2 trial, which is insufficient alone to change clinical practice without confirmatory phase 3 data. Biomarker findings require prospective validation before guiding treatment selection.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.